MLYS Mineralys Therapeutics Inc
Price (delayed)
$14
Market cap
$697.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.66
Enterprise value
$583.61M
We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone
Highlights
The company's quick ratio has surged by 61% QoQ but it fell by 40% YoY
The net income has dropped by 147% year-on-year and by 16% since the previous quarter
The EPS has dropped by 84% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of MLYS
Market
Valuations
Earnings
Shares outstanding
49.84M
Market cap
$697.7M
Enterprise value
$583.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$192.4M
Net income
-$177.81M
EBIT
-$177.81M
EBITDA
-$177.77M
Free cash flow
-$166.41M
Per share
Balance sheet
Liquidity
EPS
-$3.66
EPS diluted
-$3.66
Free cash flow per share
-$3.43
Book value per share
$3.84
Revenue per share
$0
TBVPS
$4.24
Total assets
$205.9M
Total liabilities
$14.65M
Debt
$0
Equity
$191.26M
Working capital
$190.71M
Debt to equity
0
Current ratio
14.02
Quick ratio
13.53
Net debt/EBITDA
0.64
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-62.4%
Return on equity
-68%
Return on invested capital
-105.1%
Return on capital employed
-93%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MLYS stock price
How has the Mineralys Therapeutics stock price performed over time
Intraday
1.16%
1 week
-13.31%
1 month
53.17%
1 year
11.29%
YTD
13.73%
QTD
-11.84%
Financial performance
How have Mineralys Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$192.4M
Net income
-$177.81M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 147% year-on-year and by 16% since the previous quarter
The company's operating income has shrunk by 127% YoY and by 14% QoQ
Growth
What is Mineralys Therapeutics's growth rate over time
Valuation
What is Mineralys Therapeutics stock price valuation
P/E
N/A
P/B
3.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 84% year-on-year and by 11% since the previous quarter
The stock's P/B is 50% more than its last 4 quarters average of 2.4
MLYS's equity is down by 21% year-on-year and by 19% since the previous quarter
Efficiency
How efficient is Mineralys Therapeutics business performance
MLYS's ROIC has plunged by 160% YoY and by 36% from the previous quarter
MLYS's ROE has shrunk by 157% YoY and by 22% QoQ
The ROA has dropped by 145% year-on-year and by 21% since the previous quarter
Dividends
What is MLYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MLYS.
Financial health
How did Mineralys Therapeutics financials performed over time
The current ratio has soared by 64% from the previous quarter but it has decreased by 41% YoY
The company's quick ratio has surged by 61% QoQ but it fell by 40% YoY
Mineralys Therapeutics's debt is 100% lower than its equity
MLYS's equity is down by 21% year-on-year and by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.